Trevi Therapeutics, Inc. (TRVI) Institutional Ownership

Ownership Summary

Trevi Therapeutics, Inc. (NASDAQ:TRVI) has 182 institutional investors with active 13F positions as of December 2025.

• Their combined ownership stood at 89.8% of outstanding shares in December 2025, down from 91.9% in September 2025.
• They decreased total shares held in Trevi Therapeutics by -1.71% from the prior quarter, while the number of investors in TRVI increased 63.96% year over year.
• Activity in TRVI broke down as 105 buyers, 50 sellers, and 27 unchanged among 182 total holders.
• Altogether, these fund groups held 130.26Mn shares in TRVI by December 2025, down by 2.27Mn shares quarter on quarter, and up 45.26Mn shares year over year.
• As of December 31, 2025, NEA Management Company, LLC held the largest stake in Trevi Therapeutics with 13.22Mn shares, accounting for 9.11% of total shares outstanding.
• The largest buyers of Trevi Therapeutics for the quarter ending December 2025 were FMR LLC (3.2Mn), EMERALD ADVISERS, LLC (1.89Mn), Pictet Asset Management Holding SA (1.52Mn), EMERALD MUTUAL FUND ADVISERS TRUST (1.27Mn), EVENTIDE ASSET MANAGEMENT, LLC (1.24Mn).
• Top sellers of TRVI stock for the quarter ending December 2025 included Rubric Capital Management LP (4.77Mn), Morgan Stanley (3.25Mn), Bank Of America Corp /De/ (2.58Mn), Artia Global Partners LP (1.99Mn), VIKING GLOBAL INVESTORS LP (1.93Mn).
• According to Business Quant data, leading holders of TRVI for December 2025 are NEA Management Company, LLC (13.22Mn), Frazier Life Sciences Management, L.P. (10.26Mn), BlackRock, Inc. (10.13Mn), FMR LLC (6.5Mn), VANGUARD GROUP INC (6.43Mn), Vivo Capital, LLC (5.09Mn), MARSHALL WACE, LLP (4.58Mn), Rubric Capital Management LP (3.77Mn), WELLINGTON MANAGEMENT GROUP LLP (3.4Mn), MPM BioImpact LLC (3.29Mn).